Bavarian Nordic Plans to Initiate P-III Trial of Respiratory Syncytial Virus Candidate MVA-BN
Shots:
- Bavarian Nordic plans to initiate a P-III study for its RSV vaccine MVA-BN in H1’22 which is subject to successfully raising equity capital
- In Sep’21, company reported positive results of P-II human challenge study, showing a statistically significant reduction in viral load in vaccinated vs placebo. MVA-BN vaccine showed an efficacy of up to 79% in preventing RSV infections
- Bavarian Nordic in collaboration with an undisclosed CRO plans to initiate P-III study where they plan to recruit n=20,000 across geographies with follow-up planned for 2023-24
Ref: Bavarian | Image: Bavarian
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com